ReviewBiomolecules2023
Update on Biomarkers Associated with Large-Artery Atherosclerosis Stroke.
Review in Biomolecules, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Cell apoptosis in ischemic stroke: Focus on lipid metabolism.Neural regeneration research · 2026Article
- Nighttime Systolic Blood Pressure, Neuroaxonal Injury, and Cognitive Impairment in Intracranial Atherosclerotic Stenosis.Journal of the American Heart Association · 2026Article
- Association ofRevista de neurologia · 2026Article
- Relationship between impaired glucose metabolism and bone mineral density in patients with cystic fibrosis.European journal of pediatrics · 2026Article
- Timely Initiation of Argatroban Improves Prognosis in Patients With Acute Ischemic Stroke Attributed to Large Artery Atherosclerosis: A Cohort Study.Brain and behavior · 2025Article
- Inflammatory Burden Index and One-Year Clinical Outcomes in Large Artery Atherosclerosis Ischemic Stroke: A Multicenter Prospective Study.European journal of neurology · 2025Article
- Hypercholesterolemia Duration and Brain Area Determine Inflammatory Response Intensity and Apoptotic Mediator Activation in Apo ECellular and molecular neurobiology · 2025Article
- Elevated high-sensitivity C-reactive protein levels are associated with intracranial arterial stenosis in elderly patients.BMC neurology · 2025Article
- Lipoprotein(a) as a Stroke Biomarker: Pathophysiological Pathways and Therapeutic Implications.Journal of clinical medicine · 2025Review
- Association of ApoB/apoA1 ratio with stenosis of intracranial and extracranial arteries in patients with ischaemic stroke.Scientific reports · 2025Article
- The Role of IL-6 in Ischemic Stroke.Biomolecules · 2025Review
- Nesfatin-1 as a Potential Biomarker for Ischemic Stroke: A Case-Controlled Study of a Comparative Analysis of Patients with and Without Internal Carotid Artery Stenosis.Diagnostics (Basel, Switzerland) · 2025Article
- Proteomic Analyses of Clots Identify Stroke Etiologies in Patients Undergoing Endovascular Therapy.CNS neuroscience & therapeutics · 2025Article
- Predicting Stroke-Associated Pneumonia in Acute Ischemic Stroke: A Machine Learning Model Development and Validation Study with CBC-Derived Inflammatory Indices.International journal of general medicine · 2025Article
- Prevalence, diagnosis and management of intracranial atherosclerosis in White populations: a narrative review.Neurological research and practice · 2024Review
- Identification and characterization of extrachromosomal circular DNA in large-artery atherosclerotic stroke.Journal of cellular and molecular medicine · 2024Article
- Association between atherosclerosis and the development of multi-organ pathologies.SAGE open medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracranial and extracranial large-artery atherosclerosis (LAA) are a main cause of ischemic stroke. Biomarkers may aid in the diagnosis of LAA and help to stratify patients' risk of stroke. We performed a narrative review of the literature, mainly published in the last five years, with the aim of identifying biomarkers associated either with intracranial or extracranial LAA in humans. Several potential biomarkers of LAA, mainly related to lipidic pathways and inflammation, have been studied. Diagnostic biomarkers of LAA were evaluated by measuring biomarkers levels in patients with LAA stroke and other stroke etiologies. Some biomarkers were associated with the functional prognosis of LAA stroke patients. Increased levels of IL-6 and sLOX-1 were associated with a risk of progression of carotid atherosclerotic disease. Findings support the notion that the immune system plays a central role in the pathogenesis of LAA. Overall, in most studies, results were not externally validated. In the future, biomarkers could be useful for the selection of patients for clinical trials. To adopt these biomarkers in clinical practice, we will need robust multicentric studies proving their reproducibility and a clear practical applicability for their use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.